PEOPLE - Changes at UroGen (US):
This article was originally published in Clinica
Executive Summary
US company UroGen has named Dr Robert Sobol president and chief executive officer. Dr Sobol, a founder of IDEC Pharmaceuticals, had previously been executive vice-president and chief operating officer of UroGen. He replaces Paul Quadros who becomes chairman. Dr Sobol also joins the board of directors, together with Victor Schmitt and Dr Wei-Wei Zhang, both from Baxter Healthcare. Following a partnering agreement with Baxter, Urogen has expanded its product line to include diagnostics and treatment for cancer and genetic disorders as well as prostate cancer.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.